The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S22-S32 , February 2009

Safety of Bisphosphonates in the Treatment of Osteoporosis

  • Robert R. Recker, MD

      Affiliations

    • School of Medicine, Creighton University, Omaha, Nebraska, USA
    • ,
  • E. Michael Lewiecki, MD

      Affiliations

    • New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA
    • Corresponding Author InformationRequests for reprints should be addressed to E. Michael Lewiecki, MD, New Mexico Clinical Research & Osteoporosis Center, 300 Oak Street NE, Albuquerque, New Mexico 87106
    • ,
  • Paul D. Miller, MD

      Affiliations

    • Colorado Center for Bone Research, Lakewood, Colorado, USA
    • ,
  • James Reiffel, MD

      Affiliations

    • Columbia University, New York, New York, USA

References 

  1. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122:S33–S45
  2. IMS HEALTH, National Prescription Audit Plus™, 2008.
  3. Russell R. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006;1068:367–401
  4. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617–627
  5. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581–589
  6. Lerner UH. Bone remodeling in post-menopausal osteoporosis. J Dent Res. 2006;85:584–595
  7. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res. 1988;3:133–144
  8. Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008;23:6–16
  9. Frost HM. Some ABCs of skeletal pathophysiology. IV. The transient/steady state distinction. Calcif Tissue Int. 1989;45:134–136
  10. Heaney RP. Is the paradigm shifting?. Bone. 2003;33:457–465
  11. Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?. Bone. 2000;27:13–20
  12. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437–1443
  13. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344–1352
  14. Bone HG, Hosking D, Devogelaer J-P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–1199
  15. Recker R, Lappe J, Davies KM, Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res. 2004;19:1628–1633
  16. Recker RR, Weinstein R, Chesnut CH, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int. 2004;15:231–237
  17. Recker RR, Miller PD, Ste-Marie L, Phipps RJ, Zhou X, Seeman E. Comparison of risedronate and alendronate on bone remodeling and on trabecular and cortical bone architecture: a cross-sectional study in women with postmenopausal osteoporosis on long-term bisphosphonate therapy. Bone. 2007;40(suppl 2):S260
  18. Goh S, Yang K, Koh J, Wong MK, Chua SY, Chua DT, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy. J Bone Joint Surg Br. 2007;89:349–353
  19. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301
  20. Armamento-Villareal R, Napoli N, Pinwar V, Novacek D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006;355:2048–2049
  21. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613–620
  22. Kimmel DB, Recker RR, Gallagher JC, Vaswani AS, Aloia JF. A comparison of iliac bone histomorphometric data in post-menopausal osteoporotic and normal subjects. Bone Miner. 1990;11:217–235
  23. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304–1306
  24. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19:1779–1786
  25. Little D, Ramachandran M, Schindeler A. The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br. 2007;89:425–433
  26. Goodship AE, Walker P, McNally DS, Chambers TJ, Green J, inventors. Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing. European patent application 93810808. 1994.
  27. Peter CP, Handt LK, Smith SM. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci. 1998;43:1998–2002
  28. Blank MA, Gibson GW, Myers WR, Dierckman TA, Phipps RJ, Smith PN. Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Aliment Pharmacol Ther. 2000;14:1215–1223
  29. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?. Mayo Clin Proc. 2002;77:1031–1043
  30. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther. 2000;22:1433–1442
  31. Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano). 2001;13:347–354
  32. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016–1021
  33. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259–262
  34. Schnitzer TJ, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of postmenopausal osteoporosis. Aging Clin Exp Res. 2000;12:1–12
  35. Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin. 2004;20:757–764
  36. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315–1322
  37. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008;42:36–42
  38. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006;91:2631–2637
  39. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54:1838–1846
  40. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822
  41. Papapoulos SE, Harinck HI, Bijvoet OL, Gleed JH, Fraher LJ, O'Riordan JL. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Miner. 1986;1:69–78
  42. Chesnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144–152
  43. Jodrell DI, Iveson TJ, Smith IE. Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate. Lancet. 1987;1:622
  44. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract. 2006;12:48–53
  45. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139:101–111
  46. Bock O, Boerst H, Thomasius FE, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact. 2007;7:144–148
  47. Reclast (zoledronic acid) injection [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007;
  48. Data on File, Novartis Pharma AG, Basel, Switzerland.
  49. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008;
  50. US Food and Drug Administration. Information for healthcare professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)January 7, 2008. http://www.fda.gov/CDER/drug/InfoSheets/HCP/bisphosphonatesHCP.htmAccessed June 6, 2008
  51. Adami S, Bhalla AK, Dorizzi R, et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int. 1987;41:326–331
  52. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;165:346–347
  53. Miller PD. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In:  Marcus R,  Feldman D,  Nelson D,  Rosen C editor. Osteoporosis. 3rd ed.. Burlington, MA: Elsevier; 2008;p. 1725–1742
  54. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf. 2007;6:663–672
  55. Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist. 2005;19(suppl 1):3–7
  56. Dumon JC, Magritte A, Body JJ. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner. 1991;15:257–266
  57. O'Sullivan TL, Akbari A, Cadnapaphornchai P. Acute renal failure associated with the administration of parenteral etidronate. Ren Fail. 1994;16:767–773
  58. Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG. Effects of intravenous diphosphonates on renal function. Lancet. 1983;1:1328
  59. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf. 1996;14:158–170
  60. Aredia (pamidronate) [injection prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007;
  61. Zometa (zoledronic acid) [injection prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007;
  62. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22:503–508
  63. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20:2105–2115
  64. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;741:641–648
  65. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809
  66. Adami S, Prince R, Halse J, et al. Two-year safety and tolerability profile of intravenous ibandronate injections: the DIVA study. Osteoporos Int. 2006;17(suppl 1):S69;Abstract P258
  67. Miller P, Leigh C, Ward P. Renal tolerability of intravenous ibandronate allows administration by short injection. Ann Rheum Dis. 2006;65(suppl 2):422;Abstract FRI0455
  68. Actonel (risedronate sodium tablets) [prescribing information]. Cincinnati, OH: Procter & Gamble Pharmaceuticals, Inc; 2006;
  69. Fosamax (alendronate sodium) tablets and oral solution [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc; 2006;
  70. Boniva (ibandronate sodium) tablets [prescribing information]. Nutley, NJ: Roche Laboratories Inc; 2006;
  71. Boniva (ibandronate sodium) injection [prescribing information]. Nutley, NJ: Roche Laboratories Inc; 2006;
  72. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  73. Klawansky S, Komaroff E, Cavanaugh PF, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003;14:570–576
  74. Miller PD. Is there a role for bisphosphonates in chronic kidney disease?. Semin Dial. 2007;20:186–190
  75. Miller PD. The role of bone biopsy in chronic renal failure. Clin J Am Soc Nephrol. 2008;3(suppl 1):S1–S11
  76. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106:273–278
  77. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895–1896
  78. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271:840–844
  79. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455–2461
  80. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86:516–521
  81. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–1541
  82. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082
  83. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168:826–831
  84. Cauley JA, Ensrud KE. Considering competing risks…not all black and white. Arch Intern Med. 2008;168:793–795
  85. Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008;336:813–816

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)01192-3

doi: 10.1016/j.amjmed.2008.12.004

The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S22-S32 , February 2009

Article Tools

* Image Usage & Resolution